Powder: -20°C for 3 years | In solvent: -80°C for 1 year
TG100-115 是 PI3Kγ/PI3Kδ 的选择性抑制剂,IC50分别为 83 和 235 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 273 | 现货 | ||
5 mg | ¥ 678 | 现货 | ||
10 mg | ¥ 997 | 现货 | ||
25 mg | ¥ 1,980 | 现货 | ||
50 mg | ¥ 3,660 | 现货 | ||
100 mg | ¥ 5,330 | 现货 | ||
500 mg | ¥ 10,800 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 738 | 现货 |
产品描述 | TG100-115 is a PI3Kγ/δ inhibitor (IC50: 83/235 nM), with fewer effects on PI3Kα/β. |
靶点活性 | PI3Kγ:83 nM |
体外活性 | 在患心肌梗塞的啮齿目动物和猪模型中,TG100-115(0.5-5 mg/kg)具有有效的心脏保护功能,阻止梗塞恶化,保存心机功能.在Miles实验模型中,TG100-115(1-5 mg/kg)使大鼠的水肿和炎症降低.TG100-115(5 mg/kg)可使小鼠体内Sema3A或血管内皮生长因子相关的血管通透性显著降低,表明这两种因子对血管通透性的诱导作用可能依赖于PI3Kγ/δ.在患哮喘鼠模型,TG100-115可使肺嗜酸性粒细胞增多症显著减弱,并使白细胞介素13和粘蛋白积累受到抑制. |
体内活性 | 在人脐静脉内皮细胞中,TG100-115(10 μM)不影响细胞增殖和VEGF刺激的ERK磷酸化,但会阻断其他血管内皮生长因子信号通路, 如VE-钙粘蛋白磷酸化,从而抑制血管内皮生长因子诱导的VE钙粘蛋白整体水平提高。 TG100-115(0.125-10 μM)对FGF刺激的Akt磷酸化也有抑制作用。TG100-115对PI3Kα/β的抑制效果很弱(IC50:1.2/1.3 mM)。TG100-115对血管内皮生长因子调节的p70S6和mTOR激酶磷酸化有抑制作用。 |
激酶实验 | PI3K assays: Forty mL of reaction buffer (20 mM Tris/4 mM MgCl2/10 mM NaCl, pH 7.4) containing 50 mM D-myo-phosphatidylinositol 4,5-bisphosphate substrate and the desired PI3K isoform are aliquoted to 96-well plates; kinase concentrations are 250-500 ng/well, such that linear kinetics are achieved over 90 min. TG100-115 is then added as 2.5 mL of a DMSO stock to final concentration range of 100 mM to 1 nM. Reactions are initiated by addition of 10 mL of ATP to a final concentration of 3 mM, and after 90 min, 50 mL of Kinase-Glo reagent added to quantify residual ATP levels; luminosity is measured using an Ultra 384 instrument. Control reactions omitting either TG100-115 or substrate are also performed. IC50 values are derived from experimental data by nonlinear curve fitting using Prism Version 4. |
细胞实验 | Cells plated in 96-well cluster plates (5 × 103 cells/well) are cultured in assay medium (containing 0.5% serum and 50 ng/ml VEGF) in the presence or absence of TG100-115, and cell numbers are quantified by XTT assay 24, 48, or 72 hours late(Only for Reference) |
分子量 | 346.34 |
分子式 | C18H14N6O2 |
CAS No. | 677297-51-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 9 mg/mL (25.98 mM)
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.8873 mL | 14.4367 mL | 28.8734 mL | 72.1834 mL |
5 mM | 0.5775 mL | 2.8873 mL | 5.7747 mL | 14.4367 mL | |
10 mM | 0.2887 mL | 1.4437 mL | 2.8873 mL | 7.2183 mL | |
20 mM | 0.1444 mL | 0.7218 mL | 1.4437 mL | 3.6092 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
TG100-115 677297-51-7 PI3K/Akt/mTOR signaling PI3K TG100 115 Phosphoinositide 3-kinase inhibit TG-100-115 Inhibitor TG100115 inhibitor